AU2001262345A1 - Antigenic composition comprising a polycationic peptide and inosine and cytosine - Google Patents

Antigenic composition comprising a polycationic peptide and inosine and cytosine

Info

Publication number
AU2001262345A1
AU2001262345A1 AU2001262345A AU6234501A AU2001262345A1 AU 2001262345 A1 AU2001262345 A1 AU 2001262345A1 AU 2001262345 A AU2001262345 A AU 2001262345A AU 6234501 A AU6234501 A AU 6234501A AU 2001262345 A1 AU2001262345 A1 AU 2001262345A1
Authority
AU
Australia
Prior art keywords
inosine
cytosine
polycationic peptide
antigenic composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262345A
Inventor
Michael Buschle
Alena Egyed
Karen Lingnau
Frank Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CISTEM Biotechnologies GmbH
Original Assignee
CISTEM Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CISTEM Biotechnologies GmbH filed Critical CISTEM Biotechnologies GmbH
Publication of AU2001262345A1 publication Critical patent/AU2001262345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.
AU2001262345A 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine Abandoned AU2001262345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (en) 2000-06-08 2000-06-08 ANTIQUE COMPOSITION
AT1000/2000 2000-06-08
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine

Publications (1)

Publication Number Publication Date
AU2001262345A1 true AU2001262345A1 (en) 2001-12-17

Family

ID=3683921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262345A Abandoned AU2001262345A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine

Country Status (7)

Country Link
US (2) US7148191B2 (en)
EP (1) EP1286695B1 (en)
AT (2) AT410173B (en)
AU (1) AU2001262345A1 (en)
DE (1) DE60109443T2 (en)
WO (1) WO2001093903A1 (en)
ZA (1) ZA200209479B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520200A (en) * 1999-12-22 2004-04-30 Aventis Pasteur Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
AT410173B (en) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh ANTIQUE COMPOSITION
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
ES2307568T3 (en) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh CPG TYPE NUCLEIC ACIDS AND SAME USE METHODS.
NZ526786A (en) * 2001-01-03 2006-02-24 Willmar Poultry Co Inc Methods for removal of lipopolysaccharides (LPS) from vaccines for non-human animals
JP2004519453A (en) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト Applications of polycationic compounds
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2476571A1 (en) * 2002-02-28 2003-09-04 Intercell Ag Method for isolating ligands
US20060057104A1 (en) * 2002-04-24 2006-03-16 The Regents Of The University Of California Office Of The President Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
ES2378150T3 (en) * 2002-07-03 2012-04-09 Oncovir, Inc. Method for the preparation of poly-ICLC and its uses
JP2005533855A (en) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト An antigen encoded by another reading frame from a pathogenic virus.
JP2006504687A (en) * 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Method for isolating hepatitis C virus peptide
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2004055041A2 (en) * 2002-12-13 2004-07-01 Case Western Reserve University Defensin-inducing peptides from fusobacterium
DE602004022923D1 (en) 2003-03-04 2009-10-15 Intercell Ag STREPTOCOCCUS PYOGENES ANTIGENE
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
ES2562456T3 (en) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Use of an adjuvant that induces a Th1 immune response to improve immune responses
JP2007523609A (en) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト S. epidermidis antigen
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
JP2007535894A (en) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト Streptococcus agalactier antigen I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
ES2395022T3 (en) 2003-09-19 2013-02-07 Epitopix, Llc Campylobacter polypeptides and their methods of use
CN101048172A (en) * 2004-10-29 2007-10-03 英特塞尔股份公司 Hcv vaccines for chronic hcv patients
ES2586125T3 (en) 2005-02-14 2016-10-11 Epitopix, Llc Staphylococcus aureus polypeptides and methods of use
WO2008000261A2 (en) 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
JP2009542196A (en) 2006-07-07 2009-12-03 インターセル アーゲー Small Streptococcus pyogenes antigens and their use
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CA2675379A1 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
WO2008106803A1 (en) * 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
US8236326B2 (en) 2007-05-02 2012-08-07 Intercell Ag Klebsiella antigens
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2167530A2 (en) 2007-06-18 2010-03-31 Intercell AG Chlamydia antigens
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP2247308A4 (en) * 2008-01-10 2012-04-18 Nventa Biopharmaceuticals Corp Adjuvant compositions comprising poly-ic and a cationic polymer
CA2718473A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
CN102056622B (en) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 Comprise the compositions of liposome, antigen, polynucleotide and the carrier containing the continuous phase of hydrophobic substance
ES2728949T3 (en) 2008-06-27 2019-10-29 Zoetis Services Llc Novel adjuvant compositions
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
MX339461B (en) 2009-03-23 2016-05-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
PE20121689A1 (en) 2009-10-09 2012-12-14 Sanofi Sa POLYPEPTIDES FOR BINDING TO THE RECEIVER FOR FINAL PRODUCTS OF ADVANCED GLYCOSILATION AS WELL AS COMPOSITIONS AND METHODS INVOLVING THEM
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
BR112014004896B1 (en) 2010-09-03 2023-02-14 Valneva Usa, Inc. POLYPEPTIDE ISOLATED FROM C. DIFFICILE TOXIN A AND TOXIN B PROTEINS AND USES OF THE SAME
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
WO2015042369A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
PL3244920T3 (en) 2015-01-16 2023-09-25 Zoetis Services Llc Foot-and-mouth disease vaccine
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
JP2021513840A (en) 2018-02-16 2021-06-03 ２エー ファーマ アーベー Parvovirus structural proteins for the treatment of autoimmune diseases
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
US20220233672A1 (en) 2019-05-31 2022-07-28 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
CA3194598A1 (en) 2020-10-07 2022-04-14 Valentina SCREPANTI-SUNDQUIST Cholera vaccine formulation
JP2024522385A (en) 2021-04-09 2024-06-19 ヴァルネヴァ エスイー Human metapneumovirus vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (en) * 1968-08-20 1973-03-07 R Maes PROCESS FOR PREPARING INTERFERON GENERATOR COMPLEXES
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
RS50101B (en) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for immunomodulation
CA2261892A1 (en) * 1996-07-24 1998-01-29 Michelle M. Hanna Base-protected nucleotide analogs with protected thiol groups
JP2003531128A (en) * 2000-04-14 2003-10-21 インターツェル・アクチェンゲゼルシャフト Pharmaceutical preparations containing modified peptides
AT410173B (en) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh ANTIQUE COMPOSITION

Also Published As

Publication number Publication date
EP1286695A1 (en) 2003-03-05
US20070218073A1 (en) 2007-09-20
WO2001093903A1 (en) 2001-12-13
DE60109443T2 (en) 2006-04-13
DE60109443D1 (en) 2005-04-21
EP1286695B1 (en) 2005-03-16
US20030162738A1 (en) 2003-08-28
US7148191B2 (en) 2006-12-12
AT410173B (en) 2003-02-25
ATA10002000A (en) 2002-07-15
ATE290880T1 (en) 2005-04-15
ZA200209479B (en) 2003-11-21

Similar Documents

Publication Publication Date Title
AU2001262345A1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
HUP0303428A2 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
DE60144145D1 (en) Subtilisin variant
DE60037450D1 (en) FUNF-HELIX PROTEIN
WO2003089618A3 (en) Transposon system and methods of use
ATE315404T1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
HK1052629A1 (en) Proteosome influenza vaccine
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NZ331161A (en) Synthetic HIV genes encoding envelope (env) proteins
MXPA02007478A (en) Human immunodeficiency virus vaccine.
DK1047446T3 (en) Vaccine composition for Herpes Simplex virus and methods for its use
MY133969A (en) Indoloquinazolinones
DE59902827D1 (en) Azide-free, gas generating composition
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
WO2003107400A3 (en) Acid etching mixture having reduced water content
AU2002365275A1 (en) Novel chimeric rev, tat, and nef antigens
EP1279677A4 (en) Gd3-mimetic peptides
DE69736779D1 (en) COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES
MXPA03004539A (en) Isolated luciferases and the use thereof.
AU8405798A (en) A swine hepatitis e virus and uses thereof
AU2002230579A1 (en) Calcilytic compounds
AU2002223569A1 (en) Epitopes of virus hepatitis c specifically cd4+ t lymphocytes
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof